Unicycive (NASDAQ: UNCY) boosts ATM capacity, files $50M S-3 shelf
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Unicycive Therapeutics, Inc. entered into a second amendment to its sales agreement with Guggenheim Securities to expand its at-the-market common stock offering capacity to $150,000,000. The at-the-market program allows the company to sell shares of common stock from time to time.
On the same date, Unicycive filed a Shelf Registration Statement on Form S-3, including a sales agreement prospectus, to register up to $50,000,000 of common stock for sale under this at-the-market offering. The amendment itself is incorporated by reference as an exhibit.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Original ATM capacity: $100,000,000
Revised ATM capacity: $150,000,000
New S-3 shelf ATM amount: $50,000,000
3 metrics
Original ATM capacity
$100,000,000
Aggregate offering price under prior sales agreement
Revised ATM capacity
$150,000,000
Aggregate offering price after Amendment No. 2
New S-3 shelf ATM amount
$50,000,000
Common stock registered for sale in ATM Offering
Key Terms
at the market offering, Sales Agreement, Shelf Registration Statement, Form S-3, +1 more
5 terms
at the market offering financial
"through an “at the market offering” (the “ATM Offering”) as defined in Rule 415"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Sales Agreement financial
"entered into a Sales Agreement, dated November 13, 2024, with Guggenheim Securities, LLC"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
Shelf Registration Statement regulatory
"the Company filed a Shelf Registration Statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
Form S-3 regulatory
"Shelf Registration Statement on Form S-3, which includes a sales agreement prospectus"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
Inline XBRL technical
"Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Offering Details
shelf/ATM
Offering
Offering Type
shelf/ATM
FAQ
What did Unicycive Therapeutics (UNCY) announce in this 8-K filing?
Unicycive Therapeutics announced a second amendment to its sales agreement with Guggenheim Securities, expanding its at-the-market common stock offering capacity to $150,000,000, and filed a Shelf Registration Statement on Form S-3 to register $50,000,000 of common stock for sale.
How large is Unicycive Therapeutics’ at-the-market stock program now?
The sales agreement now permits at-the-market sales of Unicycive Therapeutics’ common stock with an aggregate offering capacity of up to $150,000,000. This reflects an increase from the earlier $100,000,000 aggregate limit specified in the prior version of the sales agreement.
What amount did Unicycive Therapeutics register on the new Form S-3 shelf?
Unicycive Therapeutics filed a Shelf Registration Statement on Form S-3 covering up to $50,000,000 of its common stock. These shares may be sold from time to time through the existing at-the-market offering structure under the amended sales agreement with Guggenheim Securities.
Who is the sales agent for Unicycive Therapeutics’ ATM offering?
Guggenheim Securities, LLC serves as sales agent for Unicycive Therapeutics’ at-the-market offering. Under the amended sales agreement, Guggenheim can sell shares of Unicycive’s common stock from time to time, up to the aggregate dollar limits authorized under the agreement and registration statement.